Business
Change of Registered Office
Change of Registered Office.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n 6 September 2022\n \n \n \n \n \n \n Scancell Holdings plc\n \n \n \n (\"Scancell\" or the \"Company\")\n \n \n \n \n \n \n Change of Registered Office\n \n \n \n \n \n \n \n \n \n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease announces that it has changed its registered office address.\n \n \n \n \n \n The new registered office address for Scancell is:\n \n \n \n \n \n Bellhouse Building\n \n \n Sanders Road\n \n \n Oxford Science Park\n \n \n Oxford OX4 4GD\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Scancell Holdings plc\n \n \n \n \n \n +44 (0) 20 3727 1000\n \n \n \n \n \n \n Dr John Chiplin, Executive Chairman\n \n \n \n \n \n \n \n \n \n \n \n \n \n Professor Lindy Durrant, CEO\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Panmure Gordon (UK) Limited\n \n (Nominated Adviser and Joint Broker)\n \n \n \n \n +44 (0) 20 7886 2500\n \n \n \n \n \n \n Freddy Crossley/Emma Earl (Corporate Finance)\n \n \n \n \n \n \n \n \n \n \n \n \n \n Rupert Dearden (Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Stifel Nicolaus Europe Limited\n \n (Joint Broker)\n \n \n \n \n +44 (0) 20 7710 7600\n \n \n \n \n \n \n Nicholas Moore/\n Samira Essebiyea/William Palmer-Brown\n (Healthcare Investment Banking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n Nick Adams/Nick Harland (Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n FTI Consulting\n \n \n \n \n \n +44 (0) 20 3727 1000\n \n \n \n \n \n \n Simon Conway/Rob Winder/Alex Davis\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n About Scancell\n \n \n \n \n \n \n \n \n Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology ...